NVCR

NovoCure Ltd

16.16^post−$0.11 (−0.68%)at close +$0.00 (+0.00%)

tap the star to start your desk

as of 20:50:18 UTCnext report Oct 29 · 85d

Performance

3M−1.36%

Relationships

2 ties · EDGAR · select for source

NVCR

no disclosed suppliersNVCR sells to

what am I seeing?

Nodes sit closer to NVCR when the tie is more firmly disclosed — a named revenue weight first, then high-confidence ties, then the rest. A node's glow tracks its move today: it lifts (green) when up, sinks (red) when down, and brightens with the size. Select any node for the filing sentence behind the tie.

etf exposure · n-port

IWM0.04%VTI0.00%

Earnings

consensus

Next reportOct 29 · in 85d · before open

has moved

±13.9%

per session, last 8 reports

market-implied

±29.3%

to the next expiry after this report

Open the Earnings Roomthe report · expected movement · blast radius · the record

Earnings

loading…

Event sensitivity

computed

NFPjobs reportup 3 of 7±4.6%1.4×

CPIconsumer pricesup 2 of 8±3.8%1.2×

PCEpersonal income & outlaysup 11 of 17±3.6%1.1×

GDPgross domestic productup 9 of 17±3.6%1.1×

PPIproducer pricesup 5 of 8±2.5%0.8×

FOMCrate decisionup 8 of 24±2.4%0.7×

CPROFcorporate profitsup 7 of 10±1.7%0.5×

How NVCR has moved on past release days vs its typical ±3.2% day, and how often it closed up. Computed from daily closes — not a forecast.

Event sensitivity

loading…

News

Nothing on the wire mentions NVCR yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.

News

loading…

Overview

Medical Equipment

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.

sector: Manufacturing
chief executive: Asaf Danziger
employees: 1,320
headquarters: Jersey
listed: Nasdaq
web: novocure.com

Overview

loading…